Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-18-000287
Filing Date
2018-01-09
Accepted
2018-01-09 17:12:36
Documents
1
Period of Report
2018-01-08

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f3010218ludwig_actinium.html 3  
1 OWNERSHIP DOCUMENT f3010218ludwig_actinium.xml 3 3025
  Complete submission text file 0001213900-18-000287.txt   4471
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 21 FERNWOOD ROAD ROCKAWAY NJ 07866-2028
Business Address
Ludwig Dale L. (Reporting) CIK: 0001727406 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36374 | Film No.: 18519732